DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS

BACKGROUND: Hypermutation is an emerging biomarker for predicting response to immunotherapy in cancer patients, however its clinical value in gliomas is not established. We sought to assess the determinants of hypermutation in gliomas, and its value for predicting response to standard of care and im...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Touat, Mehdi, Li, Yvonne, Boynton, Adam, Spurr, Liam, Iorgulescu, Bryan, Birzu, Christina, Pal, Sangita, Ferrer-Luna, Ruben, Geduldig, Jack, Bellamy, Charlotte, Younan, Nadia, Baldini, Capucine, Verreault, Maite, Guillerm, Erell, Ammari, Samy, Beuvon, Frederic, Mokhtari, Karima, Alentorn, Agusti, Dehais, Caroline, Houiller, Caroline, Laigle-Donadey, Florence, Lee, Eudocia, Nayak, Lakshmi, Carpentier, Alexandre, Cornu, Philippe, mathon, Bertrand, Bi, Wenya, Chiocca, Ennio, Alexandrescu, Sanda, Chi, Susan, Haas-Kogan, Daphne, Alexander, Brian, Huang, Raymond, Ligon, Azra, Coulet, Florence, Delattre, Jean-Yves, Hoang-Xuan, Khe, Meredith, David, Santagata, Sandro, Duval, Alex, Sanson, Marc, Cherniack, Andrew, Wen, Patrick, Reardon, David, Marabelle, Aurelien, Idbaih, Ahmed, Beroukhim, Rameen, Bandopadhayay, Pratiti, Bielle, Franck, Ligon, Keith
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Drug Resistance
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847135/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.296
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi